Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis
Background Poor adherence to oral HIV pre-exposure prophylaxis (PrEP) diminishes its
clinical and public health benefits. This study synthesises evidence regarding …
clinical and public health benefits. This study synthesises evidence regarding …
HIV pre-exposure prophylaxis: scaling up for impact now and in the future
BR Bavinton, AE Grulich - The Lancet Public Health, 2021 - thelancet.com
More than a decade after the first efficacy evidence for oral HIV pre-exposure prophylaxis
(PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention …
(PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention …
Defining the HIV pre-exposure prophylaxis care continuum
Pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy. There is little
scientific consensus about how to measure PrEP program implementation progress. We …
scientific consensus about how to measure PrEP program implementation progress. We …
Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation
JL Marcus, LB Hurley, CB Hare… - JAIDS Journal of …, 2016 - journals.lww.com
Background: Placebo-controlled and open-label studies have demonstrated the safety and
efficacy of daily oral preexposure prophylaxis (PrEP) in preventing HIV infection, but data …
efficacy of daily oral preexposure prophylaxis (PrEP) in preventing HIV infection, but data …
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled …
RJ Landovitz, S Li, B Grinsztejn, H Dawood… - PLoS …, 2018 - journals.plos.org
Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being
developed for HIV treatment and prevention. CAB is formulated both as an immediate …
developed for HIV treatment and prevention. CAB is formulated both as an immediate …
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW …
Background Daily pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but few
long-term data are available on effectiveness and adherence in real-world settings. Here …
long-term data are available on effectiveness and adherence in real-world settings. Here …
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of …
CA Koss, ED Charlebois, J Ayieko, D Kwarisiima… - The lancet HIV, 2020 - thelancet.com
Background Optimal strategies for pre-exposure prophylaxis (PrEP) engagement in
generalised HIV epidemics are unknown. We aimed to assess PrEP uptake and …
generalised HIV epidemics are unknown. We aimed to assess PrEP uptake and …
PrEP rollout in Africa: status and opportunity
EM Irungu, JM Baeten - Nature medicine, 2020 - nature.com
Following recommendations by the World Health Organization in 2015, and key clinical
trials, countries in sub-Saharan Africa, the region with the highest burden of human …
trials, countries in sub-Saharan Africa, the region with the highest burden of human …
Barriers and facilitators of PrEP adherence for young men and transgender women of color
S Wood, R Gross, JA Shea, JA Bauermeister… - AIDS and Behavior, 2019 - Springer
We aimed to discover barriers and facilitators of HIV pre-exposure prophylaxis (PrEP)
adherence in young men and transgender women of color who have sex with men …
adherence in young men and transgender women of color who have sex with men …
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
JM Baeten, T Palanee-Phillips, NM Mgodi, AJ Mayo… - The lancet HIV, 2021 - thelancet.com
Background Two phase 3 clinical trials showed that use of a monthly vaginal ring containing
25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by …
25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by …